Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 3Triple Negative Breast Neoplasms 1Skin Neoplasms 1

Interventions

Nivolumab 13Ipilimumab 10pembrolizumab 8cemiplimab 6Surveys and Questionnaires 6Biopsy 6aldesleukin 5Radiotherapy 5Interleukin-2 5Blood Specimen Collection 5Temozolomide 4Sirolimus 4Photochemotherapy 4Mohs Surgery 4HhAntag691 4Fluorouracil 4Educational Status 4Cyclophosphamide 4sonidegib 3fludarabine phosphate 3fludarabine 3avelumab 3Vemurafenib 3Surgical Procedures, Operative 3Radiation 3Petrolatum 3Cetuximab 3Aminolevulinic Acid 3trametinib 2dabrafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Skin Neoplasms × Toll-Like Receptor 1 × Clear all
NCT01701674 2025-12-19

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Completed
13 enrolled 10 charts
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡